Gilead Sciences (NASDAQ:GILD) is up 19%. The big cap's treatments include those for HIV and hepatitis C. Earnings grew 208% and 372% in the past two quarters. The Street sees 269% growth in Q3. Gilead Sciences Inc. (NASDAQ:GILD) in last trading activity moved down -0.54% to close at $106.09. Company weekly performance is 10.33% while its quarterly performance stands at 17.17%. Gilead Sciences Inc. (NASDAQ:GILD) is -0.83% away from its 52 week high. Yingli Green Energy Holding Company Limited (NYSE:YGE) (Baoding, China) on October 21st, 2014 announced that it has surpassed two gigawatts (GW) of cumulative solar photovoltaic (PV) panel deliveries in the Americas. Yingli Green Energy Holding Co. Ltd. (NYSE:YGE) in last trading activity moved down -6.60% to close at $2.83. Company weekly performance is 5.99% while its quarterly performance stands at -18.68%. Yingli Green Energy Holding Co. Ltd. (NYSE:YGE) is -64.54% away from its 52 week high. BioTime, Inc. (NYSEMKT:BTX) is a biotechnology company focused on the emerging field of regenerative medicine. Its commercial strategy is focused on its line of research products, such as ACTCellerate cell lines and associated ESpan culture media, HyStem hydrogels, human embryonic stem (hES) cell lines, and royalties from Hextend. On last trading day BioTime, Inc. (NYSEMKT:BTX) moved down -3.27% to close at $3.25. Its volatility for the week is 6.25% while volatility for the month is 7.19%. BTX's sales growth for past 5 years was 24.00% and its EPS growth for past 5 years was -38.30%. BioTime, Inc. (NYSEMKT:BTX) monthly performance is -0.91%. The management team at Columbia Laboratories, Inc. (NASDAQ:CBRX) will hold a conference call on October 28(th), 2014, to discuss financial results for the third quarter ended September 30, 2014. Columbia Laboratories Inc. (NASDAQ:CBRX) has 1.50% insider ownership while its institutional ownership stands at 17.20%. In last trading activity company's stock closed at $5.89. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is in the portfolio of Palo Alto Investors managed by William Leland Edwards. However, the fund recently reduced its exposure to the stock of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by almost half. On Wednesday shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) closed at $5.63. Company's sales growth for last 5 years was -51.60%.
Discover Hidden Gems
Don't miss the next big opportunity. Subscribe for timely alerts on potential market movers.
